HMPL-760 + rituximab + gemcitabine + oxaliplatin

A four-drug combination regimen comprising **HMPL-760** (a potent, selective, reversible, third-generation Bruton’s tyrosine kinase inhibitor active against both wild-type and C481S mutant BTK), **rituximab** (a monoclonal antibody targeting CD20), **gemcitabine** (a nucleoside analog and antimetabolite), and **oxaliplatin** (a platinum-based cytotoxic chemotherapy agent). This combination is being evaluated for treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and other B-cell hematological malignancies. HMPL-760 is developed by HUTCHMED and is designed to overcome resistance mutations (such as BTK C481S) to prior BTK inhibitors. Rituximab exerts immune-mediated antitumor effects through CD20 on B cells. Gemcitabine and oxaliplatin disrupt DNA synthesis and function, contributing synergistic cytotoxicity. The combination is under clinical investigation for efficacy and safety in heavily pretreated lymphoma populations[1][2][10].

Other names

R-GemOxrituximab + gemcitabine + oxaliplatin